EP1002078A1 - Procede permettant de readministrer un vecteur viral adeno-associe via l'immunodepression de l'hote - Google Patents

Procede permettant de readministrer un vecteur viral adeno-associe via l'immunodepression de l'hote

Info

Publication number
EP1002078A1
EP1002078A1 EP98938125A EP98938125A EP1002078A1 EP 1002078 A1 EP1002078 A1 EP 1002078A1 EP 98938125 A EP98938125 A EP 98938125A EP 98938125 A EP98938125 A EP 98938125A EP 1002078 A1 EP1002078 A1 EP 1002078A1
Authority
EP
European Patent Office
Prior art keywords
antibody
patient
aav
raav
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98938125A
Other languages
German (de)
English (en)
Inventor
Varavani Dwarki
Shang-Zhen Zhou
John E. Murphy
William C. Manning
Jaime Escobedo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of EP1002078A1 publication Critical patent/EP1002078A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

L'invention concerne un procédé permettant d'appliquer à un patient une thérapie génique dans laquelle le médiateur est un vecteur viral adéno-associé. Le procédé consiste à administrer à un patient une particule de virus adéno-associé déficiente du point de vue de la réplication qui infecte une cellule du patient, la particule contenant un gène qui code une protéine nécessaire au patient, le gène étant lié de manière efficace pour l'expression dans la cellule; le procédé consiste également à administrer à peu près au moment de l'étape précédente, un immunosuppresseur qui supprime la réponse immunitaire humorale du patient. Cette invention concerne également des compositions pharmaceutique contenant le virus adéno-associé décrit précédemment et l'immuno-suppresseur humoral dans un support pharmaceutiquement acceptable. Des exemples de protéines exprimées par les vecteurs décrits précédemment comprennent l'erythropoïétine, la thrombopoïétine, le facteur de croissance humaine, la leptine, le facteur VIII, le facteur IX, le facteur Xa et autres.
EP98938125A 1997-07-31 1998-07-29 Procede permettant de readministrer un vecteur viral adeno-associe via l'immunodepression de l'hote Withdrawn EP1002078A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US5468997P 1997-07-31 1997-07-31
US5431897P 1997-07-31 1997-07-31
US5437297P 1997-07-31 1997-07-31
US5469297P 1997-07-31 1997-07-31
US54692P 1997-07-31
US54689P 1997-07-31
US54318P 1997-07-31
US54372P 1997-07-31
US5613997P 1997-08-19 1997-08-19
US56139P 1997-08-19
PCT/US1998/015794 WO1999006562A1 (fr) 1997-07-31 1998-07-29 Procede permettant de readministrer un vecteur viral adeno-associe via l'immunodepression de l'hote

Publications (1)

Publication Number Publication Date
EP1002078A1 true EP1002078A1 (fr) 2000-05-24

Family

ID=27535252

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98938125A Withdrawn EP1002078A1 (fr) 1997-07-31 1998-07-29 Procede permettant de readministrer un vecteur viral adeno-associe via l'immunodepression de l'hote

Country Status (5)

Country Link
EP (1) EP1002078A1 (fr)
JP (1) JP2001512142A (fr)
AU (1) AU8672198A (fr)
CA (1) CA2297490A1 (fr)
WO (1) WO1999006562A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221646B1 (en) 1997-07-31 2001-04-24 Chiron Corporation Materials and methods for simplified AAV production
US6464976B1 (en) 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
AU1441400A (en) * 1999-09-30 2001-05-10 Chiron Corporation Materials and methods for simplified aav production
CA2408408C (fr) 2000-05-12 2013-07-09 Genzyme Corporation Modulateurs de marquage du tnf-alpha
WO2001094605A2 (fr) * 2000-06-09 2001-12-13 University Of Florida Research Foundation, Inc. Compositions a base de vecteur viral associe a l'adenovirus et leurs utilisations therapeutiques
AU2001296354A1 (en) 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
EP2019143A1 (fr) 2007-07-23 2009-01-28 Genethon Thérapie génique du CNS utilisant l'administration périphérique de vecteurs AAV
EP2058401A1 (fr) 2007-10-05 2009-05-13 Genethon Fourniture généralisée de gènes à des motoneurones utilisant l'injection périphérique de vecteurs AAV
EP2287323A1 (fr) 2009-07-31 2011-02-23 Association Institut de Myologie Fourniture généralisée de gènes à la rétine utilisant l'administration de vecteurs AAV
JP6385920B2 (ja) 2012-05-09 2018-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティー アデノ随伴ウイルスプラスミド及びベクター
JP6417322B2 (ja) 2012-06-21 2018-11-07 アソシアシオン・アンスティテュ・ドゥ・ミオロジーＡｓｓｏｃｉａｔｉｏｎ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｍｙｏｌｏｇｉｅ 遺伝子治療ベクターの広範な遺伝子送達
CN115120746A (zh) * 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
JP7171439B2 (ja) 2016-04-15 2022-11-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症ｉｉ型を処置するための遺伝子療法
US11819539B2 (en) 2017-09-22 2023-11-21 The Trustees Of The University Of Pennsylvania Gene therapy for treating Mucopolysaccharidosis type II
WO2019104307A1 (fr) 2017-11-27 2019-05-31 Coda Biotherapeutics, Inc. Compositions et procédés de traitement de maladies neurologiques
RU2020126574A (ru) * 2018-01-11 2022-02-11 Кэмилиэн Байосайнсиз, Инк. Векторы, ускользающие от иммунного надзора, и их применение в генотерапии
KR20210130158A (ko) 2019-01-31 2021-10-29 오레곤 헬스 앤드 사이언스 유니버시티 Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
WO2021035179A1 (fr) 2019-08-21 2021-02-25 Coda Biotherapeutics, Inc. Compositions et méthodes de traitement de maladies neurologiques
WO2023212298A1 (fr) 2022-04-29 2023-11-02 Broadwing Bio Llc Anticorps bispécifiques et méthodes de traitement d'une maladie oculaire
WO2023212293A1 (fr) 2022-04-29 2023-11-02 Broadwing Bio Llc Anticorps spécifiques 4 associés au facteur h du complément et leurs utilisations
WO2023212294A1 (fr) 2022-04-29 2023-11-02 Broadwing Bio Llc Anticorps spécifiques de la protéine 7 liée à l'angiopoïétine et leurs utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9906562A1 *

Also Published As

Publication number Publication date
WO1999006562A1 (fr) 1999-02-11
JP2001512142A (ja) 2001-08-21
AU8672198A (en) 1999-02-22
CA2297490A1 (fr) 1999-02-11

Similar Documents

Publication Publication Date Title
EP1002078A1 (fr) Procede permettant de readministrer un vecteur viral adeno-associe via l'immunodepression de l'hote
Manning et al. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors
US5872154A (en) Method of reducing an immune response to a recombinant adenovirus
Zhou et al. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates
AU768729B2 (en) Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6759237B1 (en) Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
JP2023106497A (ja) 減少した免疫反応性を有するａａｖビリオン、およびその使用
US20020045264A1 (en) Production of chimeric capsid vectors
US7662627B2 (en) Adeno-associated virus materials and methods
PT764213E (pt) Vectores que codificam genomas de aav recombinates
US20060073119A1 (en) Methods for treating neurodegenerative disorders
KR20220098210A (ko) 간-특이적 유전자 요법 벡터를 이용한 유전성 혈관 부종의 치료
CA2361462A1 (fr) Induction de la tolerance a un polypeptide therapeutique
US20060281703A1 (en) Treatment of disease using an improved regulated expression system
CA3136513A1 (fr) Therapie genique de maladies hypophosphatemiques associees au facteur de croissance des fibroblastes 23
EP1845163A2 (fr) Séquences d'acides nucléiques de sérotype 1 du virus associé à l'adénovirus
AU743335B2 (en) Non-invasive administration of adeno-associated viral vectors
US20070179113A1 (en) GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
US20060292609A1 (en) Interferon-beta gene therapy using an improved, regulated expression system
WO2024094009A1 (fr) Cassette d'expression pour gène cible et son utilisation
US20080076729A1 (en) Interferon-beta gene therapy using an improved, regulated expression system
WO2007134906A1 (fr) Thérapie génique à interféron bêta faisant appel à un système d'expression régulée amélioré
CA2411186A1 (fr) Induction de l'immunotolerance a un polypeptide d'application therapeutique
WO1999055564A2 (fr) Matieres et procedes utiles en therapie genique
AU2769502A (en) Induction of tolerance to a therapeutic polypeptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030407